Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: BB-Cl-Amidine as a novel therapeutic for canine and feline mammary cancer via activation of the endoplasmic reticulum stress pathway

Fig. 1

Effect of BB-CLA on viability and tumorigenicity of canine and feline mammary cancer cell lines. a Cells were treated for 48 h with different concentrations of BB-CLA and viability was evaluated using MTT assays. Values are expressed relative to cells treated with DMSO (control). Letters indicate significant differences between doses for each cell line (one-way ANOVA) and asterisks indicate significant differences between cell lines (T-test). b Cells were treated for 6 h with 10 μM BB-CLA and probed with antibodies to Caspase-3. Representative images are shown. c Soft agar assays were established in which cells were treated with 10 μM BB-CLA or DMSO (control). Representative images after two weeks of treatment (i) and quantification of spheres (ii) are shown. Scale bar: 10 μm. *P < 0.05, ***P < 0.001, ****P < 0.0001, n = 3. Data are presented as mean ± standard deviation

Back to article page